{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:50:51Z","timestamp":1788047451942,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.pharep.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T01:10:43Z","timestamp":1540948243000},"page":"201-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-8149","authenticated-orcid":false,"given":"Ahmed A.","family":"Abdelgalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd. Aftab","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-6125","authenticated-orcid":false,"given":"Mohammad","family":"Raish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad Eldin","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd-Elwahab","family":"Hassan Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaq Ahmad","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad I.","family":"Al Jenoobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"7","key":"10.1016\/j.pharep.2018.10.018_bib0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Peng","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharep.2018.10.018_bib0010","author":"US Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.pharep.2018.10.018_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0091270010367428","article-title":"Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants","volume":"51","author":"Tanaka","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2018.10.018_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcph.434","article-title":"Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam","volume":"55","author":"Zhang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharep.2018.10.018_bib0025","author":"US Food and Drug Administration"},{"issue":"8","key":"10.1016\/j.pharep.2018.10.018_bib0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"Van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.pharep.2018.10.018_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","article-title":"Drug interactions with solid tumour-targeted therapies","volume":"89","author":"Thomas-Schoemann","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pharep.2018.10.018_bib0040","series-title":"Goodman & Gilman\u2019s pharmacological basis of therapeutics","first-page":"1731","article-title":"Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines","author":"Chabner","year":"2011"},{"issue":"6","key":"10.1016\/j.pharep.2018.10.018_bib0045","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1124\/dmd.108.025932","article-title":"Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.pharep.2018.10.018_bib0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.23776","article-title":"Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia","volume":"89","author":"Gardner","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.pharep.2018.10.018_bib0055","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.exphem.2012.04.003","article-title":"Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A","volume":"40","author":"Blake","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.pharep.2018.10.018_bib0060","author":"Novartis"},{"issue":"5","key":"10.1016\/j.pharep.2018.10.018_bib0065","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","article-title":"Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes","volume":"90","author":"Kolars","year":"1992","journal-title":"J Clin Invest"},{"issue":"2-3","key":"10.1016\/j.pharep.2018.10.018_bib0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-409X(97)00043-4","article-title":"Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery","volume":"27","author":"Hebert","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.pharep.2018.10.018_bib0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0889-8553(21)00046-7","article-title":"Drug metabolism by cytochromes P450 in the liver and small bowel","volume":"21","author":"Watkins","year":"1992","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"10.1016\/j.pharep.2018.10.018_bib0080","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1211\/jpp.58.7.0016","article-title":"Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats","volume":"58","author":"Kajita","year":"2006","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2018.10.018_bib0085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1573412911666150114230011","article-title":"Validated UPLC-MS method for pharmacokinetic investigations of cyclosporine-A in blood","volume":"11","author":"Alam","year":"2015","journal-title":"Curr Pharm Anal"},{"key":"10.1016\/j.pharep.2018.10.018_bib0090","doi-asserted-by":"crossref","first-page":"593195","DOI":"10.1155\/2012\/593195","article-title":"Camel milk triggers apoptotic signaling pathways in human hepatoma HepG2 and breast cancer MCF7 cell lines through transcriptional mechanism","volume":"2012","author":"Korashy","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"10.1016\/j.pharep.2018.10.018_bib0095","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.pharep.2018.10.018_bib0100","first-page":"145","article-title":"Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications","volume":"24","author":"Towbin","year":"1979","journal-title":"Biotechnology"},{"key":"10.1016\/j.pharep.2018.10.018_bib0105","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.biopha.2017.04.015","article-title":"Effects of Paeonia emodi on hepatic cytochrome P450 (CYP3A2 and CYP2C11) expression and pharmacokinetics of carbamazepine in rats","volume":"90","author":"Raish","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.pharep.2018.10.018_bib0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.pharep.2018.10.018_bib0115","article-title":"CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats","author":"Xu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"10.1016\/j.pharep.2018.10.018_bib0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.pharep.2018.10.018_bib0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.tox.2008.09.002","article-title":"Induction of drug metabolism: species differences and toxicological relevance","volume":"254","author":"Graham","year":"2008","journal-title":"Toxicology"},{"issue":"12","key":"10.1016\/j.pharep.2018.10.018_bib0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/00498250010021684","article-title":"determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man","volume":"30","author":"Bogaards","year":"2000","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.pharep.2018.10.018_bib0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0009-2797(01)00162-4","article-title":"Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog","volume":"134","author":"Lu","year":"2001","journal-title":"Chem Biol Interact"},{"issue":"6","key":"10.1016\/j.pharep.2018.10.018_bib0140","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/FTD.0000000000000084","article-title":"Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile","volume":"36","author":"Bleyzac","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.pharep.2018.10.018_bib0145","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-016-2038-9","article-title":"A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib","volume":"72","author":"Atiq","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pharep.2018.10.018_bib0150","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.pharep.2018.10.018_bib0155","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.pharep.2018.10.018_bib0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol Sin"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018301944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018301944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:49Z","timestamp":1752611869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.10.018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1734114018301944"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.10.018","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}